Liraglutide

In human trials

• 3 mg

  under the skin · daily

  Liraglutide for Low-responders After Bariatric SurgeryNA · NCT04643301

  “Daily subcutaneous injection of 3.0mg liraglutide (GLP-1 antagonist) for low-responders 3 months after bariatric surgery..”

• See source wording

  under the skin · daily · for 28 weeks

  Gut Microbiome Changes Following Liraglutide Treatment in Obese Subjects or Overweight Subjects With Co-morbiditiesPHASE3 · NCT04525300

  “Eligible patients were randomly assigned, in a 2:1 ratio, to receive once-daily subcutaneous injections of liraglutide, starting at a dose of 0.6 mg with weekly 0.6-mg increments to 3.0 mg, or placebo; both groups received counseling on lifestyle modification.”

• 1.8 mg

  daily

  Study of Liraglutide in Individuals With Type 2 Diabetes Using InsulinPHASE3 · NCT01628445

  “liraglutide titrated to 1.8 mg sc daily.”

• See source wording

  by mouth · once per day

  Liraglutide as Add on Therapy on Metformin in Women With Polycystic Ovary SyndromePHASE4 · NCT02483299

  “In the metformin group metformin was initiated at a dose of 500 mg once per day and increased by 500 mg every 3 days up to 1000 mg BID per os..”

• See source wording

  single dose

  A Trial to Investigate the Single Dose Pharmacokinetics of Insulin Degludec/Liraglutide Compared With Insulin Degludec and Liraglutide in Healthy Chinese SubjectsPHASE1 · NCT03292185

  “Insulin Degludec/Liraglutide combination product with 0.61 mg Liraglutide and 17 U Insulin Degludec, single dose administration under the skin in the thigh..”

• See source wording

  once daily

  Liraglutide in the Treatment of Type 1 Diabetes MellitusPHASE3 · NCT01722266

  “Patients randomized to 1.2 mg of liraglutide : They will start liraglutide 0.6 mg sc once daily for one week and will increase the dose to 1.2 mg sc once daily thereafter.”

• 1.5 mg

  under the skin · weekly · for 52 weeks

  Researching an Effect of GLP-1 Agonist on Liver STeatosis (REALIST)PHASE4 · NCT03648554

  “dulaglutide (TRULICITY®) 1.5 mg.”

• See source wording

  under the skin · daily · for 1 week

  Liraglutide 3mg (Saxenda) on Weight, Body Composition, Hormonal and Metabolic Parameters in Obese Women With PCOSPHASE3 · NCT03480022

  “daily sc injection of liraglutide with final dose of 3mg daily.”

• See source wording

  under the skin · once daily · for 1 week

  Short Term Effect of Liraglutide Versus Vildagliptine on Insulin Secretion and Insulin Sensitivity in Type 2 DiabetesPHASE4 · NCT02832999

  “Liraglutide 1.2mg/day.”

• See source wording

  under the skin · daily

  Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?PHASE4 · NCT04781998

  “liraglutide 3 mg (Saxenda®) once-daily.”

• See source wording

  once per day · for 3 days

  Liraglutide in Obesity and Diabetes: Identification of CNS Targets Using fMRIPHASE4 · NCT01562678

  “Subjects will start the treatment with a dose of 0.6 mg for the first week, then 1.2 mg for the second week and 1.8 mg for 3 days in the third week..”

• 6 MG/ML

  2 times a day

  Treatment of Bile Acid Malabsorption With LiraglutidePHASE4 · NCT03955575

  “Liraglutide 6 MG/ML.”

• See source wording

  under the skin · daily · for 12 weeks

  Glucagon-like Peptide-1 and Coronary Microvascular Dysfunction in Women With Angina Pectoris and no Coronary StenosisPHASE4 · NCT02602600

  “* Liraglutide up to 3 mg daily injected subcutaneously (minimum 1.2 mg daily) for 12 weeks.”

• See source wording

  Trial for People With Established Type 2 Diabetes During RamadanPHASE4 · NCT02292290

  “4 week lead-in 0.6mg Liraglutide OD up to 1.2mg OD after 2 weeks if poor response.”

• 0.75 mg

  under the skin · single dose

  Metabolism and Excretion of Liraglutide in Healthy Male VolunteersPHASE1 · NCT01517568

  “A single dose of 0.75 mg will be given as a subcutaneous injection.”

• 0.6 mg

  under the skin

  The Effect of Liraglutide on the GITPHASE4 · NCT04008290

  “0.6 mg Liraglutide.”

• 3 mg

  once daily

  SCALE KIDS: Research Study to Look at How Well a New Medicine is at Lowering Weight in Children With ObesityPHASE3 · NCT04775082

  “Liraglutide 3.0 mg.”

• 3 mg

  once daily

  3mg Liraglutide for Overweight or ObesityNot stated · NCT03885297

  “Patients will be recruited prospectively from the weight management and Polycystic Ovary Syndrome (PCOS) clinics at University Hospitals Coventry and Warwickshire (UHCW) NHS Trust following discussion with their treating physician, who will also be a member of the research team and joint agreement on initiation of treatment with 3mg Liraglutide once daily as per clinical management plan.”

• See source wording

  once per day

  Use of a GLP-1R Agonist to Treat Opioid Use DisorderPHASE1, PHASE2 · NCT04199728

  “Participants randomized to liraglutide will be started at a low dose (0.6 mg once per day) which will be gradually increased until 1.8 mg/day is reached for the 3-dose intervention and 3 mg/day is reached for the 5-dose intervention.”

• 1.8 mg/day

  under the skin · for 4 weeks

  Effect of Liraglutide Compared to Glimepiride on Appetite in Subjects With Type 2 DiabetesPHASE1 · NCT01511692

  “1.8 mg/day injected subcutaneously for 4 weeks.”

• See source wording

  by mouth · daily

  Study of the Cardiometabolic Effects of Obesity PharmacotherapyPHASE4 · NCT04575194

  “Liraglutide 6 MG/ML [Saxenda].”

• 1.8 mg/day

  Effects of Liraglutide on Hippocampal Structure and Function in Aging Adults With PrediabetesPHASE1 · NCT02140983

  “90 days of liraglutide up to 1.8mg/day..”

• See source wording

  under the skin · single dose

  Comparison of Two Liraglutide Formulations in Healthy SubjectsPHASE1 · NCT01515579

  “One single dose of 6.25 mg/mL administered subcutaneously.”

• 3 mg

  under the skin · once daily

  Effect and Safety of Liraglutide 3.0 mg in Subjects With Overweight or Obesity and Type 2 Diabetes Mellitus Treated With Basal InsulinPHASE3 · NCT02963922

  “Liraglutide 3.0 mg.”

• See source wording

  by mouth

  Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic PatientsNA · NCT02324842

  “canagliflozin (film-coated tablet), 100 mg/day, increased to 300 mg/day after week two if tolerated without side effects.”

• See source wording

  under the skin · once a day

  The Efficacy and Safety of Liraglutide on Body Weight Loss in Obese and Overweight PatientsPHASE3 · NCT04605861

  “The initial dose of Liraglutide Injection will be 0.6 mg per day.”

• See source wording

  once daily · for 12 weeks

  Vildagliptin Versus Liraglutide - Patient Preference After Receiving Both MedicationsPHASE4 · NCT01518101

  “Single pill combination of Vildagliptin/ Metformin (50/1000 mg)..”

• See source wording

  weekly · for 4 weeks

  Effects of XW003 Versus Liraglutide on Body Weight of Adult Participants With ObesityPHASE2 · NCT05111912

  “XW003 (from 0.2 mg to 1.2 mg, 1.8 mg, and 2.4 mg once weekly), should take place during the first 14 weeks after randomization as described: Dose Escalation Schedule of Investigational Product (XW003).”

• 10 mcg

  for 2 weeks

  Evaluation of Lixisenatide Efficacy in Diabetes Mellitus Type 2 With Failure of Other GLP-1 AnalogPHASE4 · NCT02767596

  “Lixisenatide 10 mcg for 2 weeks and then 10 mcg for 10 weeks”

• 1.8 mg

  daily · for 26 weeks

  LIPT - Liraglutide in Polycystic Ovary SyndromePHASE4 · NCT02073929

  “1,8mg daily for 26 weeks.”

• 7.5 mcg/kg

  under the skin · single dose

  Effect of Liraglutide on Glucagon Secretion in Subjects With Type 2 DiabetesPHASE1 · NCT01509742

  “Single dose of 7.5 mcg/kg, injected subcutaneously followed by a hypoglycaemic clamp by concentration measurement.”

• See source wording

  under the skin · daily · for 12 weeks

  Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 DiabetesPHASE2 · NCT02057172

  “HM11260C (0.3 mg).”

• See source wording

  under the skin · once daily · for 16 weeks

  Targeting Beta-cell Failure in Lean Patients With Type 2 DiabetesPHASE4 · NCT04657939

  “Liraglutide 0.6mg once daily by subcutaneous injection escalated to 1.2mg after 2 weeks..”

• See source wording

  under the skin · weekly

  GLP-1 Receptor Agonist in Primary Intracerebral Hemorrhage: A Phase 2 Randomized TrialPHASE2 · NCT07613437

  “Semaglutide, 0.5 mg/mL.”

• See source wording

  under the skin · once daily · for 26 weeks

  Efficacy and Safety of Liraglutide in Combination With Metformin Compared to Metformin Alone, in Children and Adolescents With Type 2 DiabetesPHASE3 · NCT01541215

  “Administered subcutaneously (s.c., under the skin) once daily.1.8 mg or maximum tolerated dose (MTD: 0.6 mg, 1.2 mg, 1.8 mg) for 26 weeks.”

• See source wording

  Study of the Safety and Tolerability of Switching to ITCA 650 in Patients With Type 2 Diabetes Receiving LiraglutidePHASE3 · NCT02638805

  “ITCA 650 Osmotic Mini Pump 20/60 mcg/day.”

• See source wording

  into a vein · once daily · for 12 weeks

  SAFEGUARD: Pleiotropic Effects of Incretin Based TherapiesPHASE4 · NCT01744236

  “Liraglutide will be started with a titration period of 2 weeks (week 1: 0.6mg once daily and week 2: 1.2mg once daily).”

• See source wording

  daily

  A Pilot Study of the Effects on Sleep Disordered Breathing (SDB) When Using the Drug Liraglutide for 4 WeeksPHASE1, PHASE2 · NCT01832532

  “Titrated up from 0.6mg/day to 1.8mg/day or highest tolerated dose.”

• See source wording

  once daily

  A Trial to Assess the Effect of Liraglutide on Gastric Emptying in Healthy Obese VolunteersPHASE1 · NCT00978393

  “High dose liraglutide treatment (3.0 mg) followed by low dose liraglutide treatment (1.8 mg).”

• See source wording

  every 4 weeks · for 1 week

  Pilot Study of the Effect of Liraglutide 3.0 mg on Weight Loss and Gastric Functions in ObesityPHASE2 · NCT03523273

  “Initiate at 0.6mg S.C.”

• See source wording

  under the skin · single dose

  Comparison of Liraglutide Inhaled Into the Lungs Compared to Liraglutide Injected Under the Skin in Healthy Male VolunteersPHASE1 · NCT01511159

  “Single dose of 6 mcg/kg by inhalation.”

• See source wording

  Study to Assess the Efficacy and Safety of Liraglutide in the Treatment of Type 2 DiabetesPHASE3 · NCT04373967

  “TQZ2451 injection (0.6mg qd from baseline to week 1;1.2mg qd during week 2;1.8mg qd from week 3 to week 26) + metformin hydrochloride sustained-release tablets (1500-2000mg qd).”

• See source wording

  by mouth

  Effect of Liraglutide or Glimepiride Added to Metformin on Blood Glucose Control in Subjects With Type 2 DiabetesPHASE3 · NCT00614120

  “0.6 mg/day, s.c.”

• See source wording

  under the skin · for 3 months

  Clinical Study on the Improvement of Diabetic Neuropathic Pain by LiraglutideNA · NCT04137328

  “0.6mg/day in the first week, if there is no obvious discomfort, 1.2mg/day in the second week, subcutaneous injection, lasting for 3 months.”

• 1.8 mg

  under the skin · daily

  The Lira Pump TrialPHASE2, PHASE3 · NCT02351232

  “Liraglutide; daily subcutaneous injection; 1.8 mg; 6 months.”

• See source wording

  under the skin · every 3 days

  Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)PHASE4 · NCT03087032

  “The starting liraglutide dose was 0.6mg/day, then 1.2mg/day after 1 week and 1.8mg/day after a further week.”

• 0.75 mg

  under the skin · single dose

  Safety and Tolerability of Liraglutide in Subjects With Impaired Kidney Function and in Subjects With Normal Kidney FunctionPHASE1 · NCT01508806

  “Single dose of 0.75 mg, administered as a subcutaneous injection.”

• See source wording

  under the skin · weekly · for 26 weeks

  A Study of LY2189265 in Japanese Participants With Type 2 Diabetes MellitusPHASE3 · NCT01558271

  “Once-weekly subcutaneous (SC) injection of 0.75 milligrams (mg) of LY2189265 for 26 weeks of blinded therapy, followed by once-weekly SC injection of 0.75 mg LY2189265 for an additional 26 weeks of open therapy..”

• See source wording

  weekly · for 52 weeks

  A Monotherapy Study to Evaluate the Efficacy and Safety of 2 Dose Levels of Albiglutide in Japanese Subjects With Type 2 Diabetes Mellitus (T2DM)PHASE3 · NCT01733758

  “Albiglutide 30 mg weekly.”

• See source wording

  under the skin · daily

  Impact of Liraglutide on Sensory Perception, Sensory Specific Satiety, Liking and Wanting in Type 2 Diabetic PatientsNA · NCT01599338

  “The initial dose was 0.6 mg/day subcutaneously during five days, then uptitrated to a daily dose of 1.2 mg during three months..”

• See source wording

  under the skin · once daily

  Randomisation to Endobarrier Alone Versus With Incretin Analogue in SustainEd Diabesity (REVISE-Diabesity)PHASE4 · NCT02055014

  “Liraglutide 1.8mg once daily subcutaneous injection.”

• See source wording

  daily · for 11 months

  Weight Loss With Intensive Lifestyle Modifications Plus Bariatric Surgery Versus Liraglutide 3 mgNA · NCT03534310

  “LIRAGLUTIDE 3 Mg/0.5 mL (18 Mg/3 mL) SUB-Q PEN INJECTOR (ML).”

• 1.8 mg

  under the skin · daily

  Incretin-based Therapy in Late Preclinical Type 1 DiabetesPHASE2 · NCT02898506

  “Daily subcutaneous injections with increasing doses up to 1.8 mg per day.”

• See source wording

  by mouth · once daily

  To Evaluate the Effect of Liraglutide Versus Glimepiride (Amaryl®) on Haemoglobin A1cPHASE3 · NCT00294723

  “1.8 mg for s.c.”

• See source wording

  daily

  The Effect of Simple Basal Insulin Titration, Metformin Plus Liraglutide for Type 2 Diabetes With Very Elevated HbA1c - The SIMPLE StudyPHASE4 · NCT01966978

  “Metformin will be started at 500 mg daily (or continued at current dose)and weekly titrated to 2000 mg or maximum tolerated dose (at least 1000 mg/day).”

• 1.2 mg

  Effects of Liraglutide on Kidney Function in Type 2 Diabetic PatientsPHASE4 · NCT01664676

  “1.2 mg liraglutide sc.”

• 1.8 mg

  under the skin · once daily

  The Effect of Liraglutide Versus Placebo When Added to Basal Insulin Analogues With or Without Metformin in Subjects With Type 2 DiabetesPHASE3 · NCT01617434

  “Maximum 1.8 mg administered s.c.”

• 1 mg

  under the skin · single dose

  Comparison of the Effect of Liraglutide in Young Versus Elderly Healthy VolunteersPHASE1 · NCT01507337

  “A single dose of 1 mg administered subcutaneously (under the skin).”

• See source wording

  Liraglutide Efficacy on Glucocorticoid Induced Hyperglycemia in Patients High Risk for DiabetesPHASE3 · NCT02016846

  “Liraglutide, tapered from 0.6 mg/day to 1.8 mg/day.”

• See source wording

  single dose · for 1 week

  Antidiabetic Effects of Adding a DPP-4 Inhibitor to Pre-Existing Treatment With an Incretin Mimetic in Patients With T2DPHASE3 · NCT01937598

  “Patients on metformin monotherapy will, after screening and randomization, enter a run-in period of 2 weeks with the additional treatment of liraglutide (0.6 mg/d for 1 week followed by 1.2 mg/d for another week) that will be continued for the entire duration of the study..”

• See source wording

  under the skin · daily

  Combined Effects of GLP-1 Analogue and Exercise on Maintenance of Weight Loss and Health After Very-low Calorie DietPHASE4 · NCT04122716

  “Daily injections (3mg) with weight consultations starting at dose of 0.6 mg injections with 0.6 mg increments weekly until 3.0 mg is achieved.”

• See source wording

  by mouth

  Efficacy and Safety of Liraglutide in Type 2 Diabetes With Lower Extremity Arterial DiseasePHASE4 · NCT04146155

  “Liraglutide is available if pre-filled pens (6 mg/ml) as a solution for injection (Victoza®).”

• See source wording

  under the skin · weekly · for 5-6 weeks

  A Randomised, Double-blind, Placebo-controlled Trial to Assess Safety, Tolerability and Pharmacokinetics of Liraglutide in Obese Adolescent Subjects Aged 12 to 17 YearsPHASE1 · NCT01789086

  “Initial dose of 0.6 mg/day.”